10x Genomics CEO sells 16,152 shares under plan

10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported planned share sales and a gift of stock.

Rhea-AI Filing Summary

10x Genomics, Inc. Chief Executive Officer Serge Saxonov reported planned share sales and a gift of stock. On March 2, 2026, he sold a total of 16,152 shares of Class A common stock in open-market transactions at weighted average prices of $22.6690 and $23.1781, effected under a Rule 10b5-1 trading plan adopted on November 29, 2025. On March 3, 2026, he made a bona fide gift of 2,750 shares at no consideration. After these transactions, he directly held 1,200,917 shares of Class A common stock, and also had indirect holdings of 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 58,000 shares in the Y/S Pot Trust, for which he serves as trustee.

Insider Trade Summary

Net Seller: 18,902 shares

Net Sell 6 txns

Insider Saxonov Serge

Role Chief Executive Officer

Sold 16,152 shs ($367K)

Type	Security	Shares	Price	Value
Gift	Class A Common Stock	2,750	$0.00	$0.00
Sale	Class A Common Stock	14,292	$22.669	$324K
Sale	Class A Common Stock	1,860	$23.1781	$43K
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 1,200,917 shares (Direct); Class A Common Stock — 271,277 shares (Indirect, See footnote)

Footnotes (6)

1. F1. The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $22.15 to $23.145, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. This transaction was executed in multiple trades at prices ranging from $23.15 to $23.25, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
4. F4. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
5. F5. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
6. F6. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

FAQ

What insider transactions did 10x Genomics (TXG) CEO Serge Saxonov report?

Serge Saxonov reported selling 16,152 shares of 10x Genomics Class A common stock and making a bona fide gift of 2,750 shares. The sales occurred on March 2, 2026, and the gift on March 3, 2026, as disclosed in a Form 4 filing.

At what prices did the 10x Genomics (TXG) CEO sell his shares?

The CEO sold 14,292 shares at a weighted average price of $22.6690 and 1,860 shares at a weighted average price of $23.1781. Both trades were executed in multiple transactions within stated price ranges, as described in the Form 4 footnotes.

Was the 10x Genomics (TXG) CEO’s stock sale pre-planned under a Rule 10b5-1 plan?

Yes. The Form 4 states that the reported transactions were effected under Serge Saxonov’s Rule 10b5-1 trading plan adopted on November 29, 2025. Such plans allow pre-arranged trades according to preset instructions, helping separate trading decisions from day-to-day information.

How many 10x Genomics (TXG) shares does the CEO own after these transactions?

After the reported transactions, Serge Saxonov directly held 1,200,917 shares of Class A common stock. He also had indirect holdings of 27 shares in the Andromeda Trust, 213,250 shares in the Y/S Descendants' Trust, and 58,000 shares in the Y/S Pot Trust, where he serves as trustee.

What does the bona fide gift reported by the 10x Genomics (TXG) CEO involve?

The filing shows a bona fide gift of 2,750 shares of Class A common stock at a price of $0.0000 per share, meaning no consideration was received. This transaction is coded as “G” on the Form 4, indicating a gift transfer rather than a sale.

How are the trust holdings reported in the 10x Genomics (TXG) Form 4 characterized?

The Form 4 notes that 27 shares are held by the Andromeda Trust, 213,250 by the Y/S Descendants' Trust, and 58,000 by the Y/S Pot Trust. Each trust position is reported as indirect ownership, with Serge Saxonov serving as trustee for these trusts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 04:14 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saxonov Serge

(Last) (First) (Middle)

10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CA 94588

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/02/2026		S(1)		14,292	D	$22.669(2)	1,205,527	D
Class A Common Stock	03/02/2026		S(1)		1,860	D	$23.1781(3)	1,203,667	D
Class A Common Stock	03/03/2026		G		2,750	D	$0	1,200,917	D
Class A Common Stock								27	I	See footnote(4)
Class A Common Stock								213,250	I	See footnote(5)
Class A Common Stock								58,000	I	See footnote(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

2. This transaction was executed in multiple trades at prices ranging from $22.15 to $23.145, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $23.15 to $23.25, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

5. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

6. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

	/s/ Randy Wu, as Attorney-in-Fact for Serge Saxonov	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.